Browse
Explore conditions, clinical trials, and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
116076 trials found · Page 736 of 5804
-
New trial tests best timing for rectal cancer chemo
Disease control Recruiting nowThis is a multicenter, prospective, randomized, stratified, controlled, open-label study comparing preoperative FOLFOX versus postoperative risk-adapted chemotherapy in patients with locally advanced rectal cancer and low risk for local failure
Phase: PHASE3 • Sponsor: Ralf Hofheinz • Aim: Disease control
Last updated Jun 27, 2026 09:01 UTC
-
New PNH drug crovalimab faces off against eculizumab in phase 3 trial
Disease control OngoingA study designed to evaluate the safety of crovalimab with eculizumab in participants with PNH currently treated with complement inhibitors. This study will enroll approximately 190 participants.
Phase: PHASE3 • Sponsor: Hoffmann-La Roche • Aim: Disease control
Last updated Jun 27, 2026 12:25 UTC
-
New combo therapy aims to shrink spleens in bone marrow cancer patients
Disease control CompletedMyelofibrosis is a type of bone marrow cancer that usually develops slowly and disrupts body's normal production of blood cells. It causes bone marrow scarring, leading to severe anemia that can cause weakness and fatigue. It can also cause a low number of blood-clotting cells ca…
Phase: PHASE3 • Sponsor: AbbVie • Aim: Disease control
Last updated Jun 27, 2026 12:00 UTC
-
New combo therapy shows promise for hard-to-treat lung cancer
Disease control CompletedETOP 15-19 ABC-lung is an international, multi-centre open-label, randomized phase II trial with two non-comparative parallel arms of atezolizumab plus bevacizumab with carboplatin-paclitaxel (Arm A) or atezolizumab, bevacizumab and pemetrexed (Arm B) in patients with stage IIIB-…
Phase: PHASE2 • Sponsor: ETOP IBCSG Partners Foundation • Aim: Disease control
Last updated Jun 27, 2026 12:31 UTC
-
Gene therapy for sanfilippo a: does it last?
Disease control ENROLLING_BY_INVITATIONThe main objective of this study is to evaluate the safety/tolerability and efficacy of UX111 (previously known as ABO-102) in participants with Mucopolysaccharidosis IIIA (MPS IIIA).
Phase: PHASE3 • Sponsor: Ultragenyx Pharmaceutical Inc • Aim: Disease control
Last updated Jul 19, 2026 00:00 UTC
-
New combo therapy shows promise for Drug-Resistant lung cancer
Disease control OngoingThis study will compare the activity of the combination of savolitinib and osimertinib against the combination of savolitinib with placebo to osimertinib in patients with Epidermal Growth Factor Receptor Mutation Positive and MET amplified, locally advanced or metastatic non-smal…
Phase: PHASE2 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Jun 27, 2026 09:08 UTC
-
New combo aims to wipe out hidden breast cancer cells after standard treatment
Disease control Recruiting nowThis study looks to advance a novel and potent strategy to eliminate minimal residual disease (MRD) in triple negative breast cancer (TNBC) present even after multimodal treatment, thereby improving survival and increasing cure rate in this aggressive cancer. Patients with locall…
Phase: PHASE1, PHASE2 • Sponsor: University of Southern California • Aim: Disease control
Last updated Jun 27, 2026 11:00 UTC
-
New drug shows promise for rare joint tumor
Disease control OngoingThis study will assess pexidartinib in adult participants with symptomatic TGCT that is associated with severe morbidity or functional limitations and not amendable to improvement with surgery.
Phase: PHASE3 • Sponsor: Daiichi Sankyo Co., Ltd. • Aim: Disease control
Last updated Jun 28, 2026 00:00 UTC
-
Promising combo targets hard-to-treat childhood cancer
Disease control OngoingDifluoromethylornithine (DFMO) will be used in an open label, multicenter, study in combination with etoposide for subjects with relapsed/refractory neuroblastoma.
Phase: PHASE2 • Sponsor: Giselle Sholler • Aim: Disease control
Last updated Jul 10, 2026 00:00 UTC
-
Glowing tumor surgery: new hope for kids with brain cancer?
Disease control CompletedIn this prospective, open, single-armed, multicenter, phase II study for application of 5-ALA in children and adolescents with brain tumors 80 patients will be investigated. Primary objective of the study is to determine the safety of 5-ALA for fluorescence-guided resections in …
Phase: PHASE2 • Sponsor: Universität Münster • Aim: Disease control
Last updated Jun 27, 2026 08:03 UTC
-
Hospital heart pill may prevent repeat crises
Disease control CompletedThis is an international, multicenter, parallel-group, randomized, double-blind, placebo-controlled trial in patients who have been stabilized during hospitalization for acute heart failure, evaluating the effect of in-hospital initiation of dapagliflozin versus placebo on the cl…
Phase: PHASE4 • Sponsor: The TIMI Study Group • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New hope for rare liver disease: drug shows promise in reducing damage and symptoms
Disease control OngoingThe participants of this study will have confirmed Primary Biliary Cholangitis (PBC) with inadequate response or intolerance to ursodeoxycholic acid (which is a medication used in the management and treatment of cholestatic liver disease). PBC is a slowly progressive disease cha…
Phase: PHASE3 • Sponsor: Ipsen • Aim: Disease control
Last updated Jul 04, 2026 00:00 UTC
-
New triple-drug attack aims to revive immune response in hard-to-treat melanoma
Disease control Recruiting nowThe purpose of this study is to find out if the administration of Interleukin-2 concurrently with ipilimumab followed by Nivolumab will result in improved anti-cancer activity and if it is effective for advanced melanoma.
Phase: PHASE2 • Sponsor: H. Lee Moffitt Cancer Center and Research Institute • Aim: Disease control
Last updated Jun 27, 2026 12:02 UTC
-
Could Lab-Grown eye cells restore sight in dry AMD?
Disease control Recruiting nowBackground: Age-related macular degeneration is a common eye disease in people over 50. The "dry" form of the disease can worsen into geographic atrophy, causing blind spots. Researchers want to learn if replacing older eye cells with younger ones can help treat this disease. O…
Phase: PHASE1, PHASE2 • Sponsor: National Eye Institute (NEI) • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
New combo therapy aims to slow advanced breast cancer
Disease control OngoingThis research study is evaluating the safety and effectiveness of Sacituzumab Govitecan with or without Pembrolizumab in metastatic HR+/HER2- breast cancer. The names of the study interventions involved in this study are: * Sacituzumab govitecan (IMMU-132) * Pembrolizumab (Keyt…
Phase: PHASE2 • Sponsor: Ana C Garrido-Castro, MD • Aim: Disease control
Last updated Jun 27, 2026 08:11 UTC
-
New drug combo shows promise for Hard-to-Treat cancers
Disease control OngoingThis is a Phase 1/2A, open label, multicenter, nonrandomized, multiple dose, safety, tolerability, pharmacokinetic and pharmacodynamic study of PF-07220060 administered as a single agent and then in combination with endocrine therapy. The study consists of two parts and a China …
Phase: PHASE2 • Sponsor: Pfizer • Aim: Disease control
Last updated Jun 27, 2026 07:53 UTC
-
Heart stent showdown: which device works best for blocked arteries?
Disease control OngoingMultivessel TALENT is a prospective, randomized, multi-center study comparing clinical outcomes between SUPRAFLEX Cruz and SYNERGY in approximately 1550 patients with de-novo three vessel disease undergoing percutaneous coronary intervention (PCI). Patients will be treated accord…
Phase: NA • Sponsor: National University of Ireland, Galway, Ireland • Aim: Disease control
Last updated Jun 27, 2026 09:08 UTC
-
New hope for advanced stomach cancer: drug combo aims to extend survival
Disease control Recruiting nowThis is a study for participants with advanced gastric or gastroesophageal junction adenocarcinoma who have had tumor progression after first-line platinum-contained therapy. The primary study hypotheses are that camrelizumab (SHR-1210) combined with apatinib prolongs overall sur…
Phase: PHASE3 • Sponsor: Jiangsu HengRui Medicine Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 08:12 UTC
-
New hope for glioblastoma? early trial combines drug with radiation
Disease control OngoingThis phase I trial investigates the side effects and best dose of Peposertib, and to see how well it works in combination with radiation therapy in treating patients with newly diagnosed MGMT unmethylated glioblastoma or gliosarcoma. Radiation therapy uses high energy x-rays to k…
Phase: PHASE1 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jul 01, 2026 00:00 UTC
-
New urine test could spare bladder cancer patients from failed treatments
Diagnosis Recruiting nowTo date, there are no diagnostics capable of predicting treatment response to intravesical BCG. Because of this severe limitation, nearly 50% of patients treated with BCG fail therapy and will a) require additional intravesical therapy or b) require cystectomy. A urine-based diag…
Sponsor: Cedars-Sinai Medical Center • Aim: Diagnosis
Last updated Jul 08, 2026 00:00 UTC